Invention Grant
- Patent Title: Benzimidazol-2-amines as mIDH1 inhibitors
-
Application No.: US15118154Application Date: 2015-02-10
-
Publication No.: US09957235B2Publication Date: 2018-05-01
- Inventor: Hartmut Rehwinkel , Olaf Panknin , Sven Ring , Sonja Anlauf , Holger Siebeneicher , Duy Nguyen , Wolfgang Schwede , Marcus Bauser , Katja Zimmermann , Stefan Kaulfuss , Roland Neuhaus , Paul Matthew Blaney
- Applicant: Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Berlin
- Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
- Current Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
- Current Assignee Address: DE Berlin
- Agency: Morrison & Foerster LLP
- Priority: EP14154680 20140211; EP14182002 20140822
- International Application: PCT/EP2015/052676 WO 20150210
- International Announcement: WO2015/121210 WO 20150820
- Main IPC: C07D235/30
- IPC: C07D235/30 ; A61K31/4184 ; A61K31/4439 ; A61K45/06 ; C07D401/12

Abstract:
The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.
Public/Granted literature
- US20170197921A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Public/Granted day:2017-07-13
Information query